Registration
Follow us on
  • Linkedin
  • Twitter
  • Facebook
  • Google+
Bose_Rathindra

Dr. Rathindra Bose

16:30|Session 4 (Stage 1)

Drug Development from Laboratory to Market Place: Opportunities and Challenges

Dr. Bose has discovered a new class of anticancer agents that exhibits superior efficacy with reduced toxicity in preclinical experiments compared to existing anticancer drugs and further continues his research.

Dr. Rathindra Bose received his Ph.D. degree in chemistry from Georgetown University, Washington D.C., in 1982. Currently, he is serving as the Vice Chancellor and Vice President for Research and Technology Transfer at the University of Houston System and University of Houston. He received a distinguished scholar award and four outstanding/distinguished teaching awards.  He was also nominated for the 1997 CASE U.S. Professor of the year award by Kent State University.

Dr. Bose has discovered a new class of anticancer agents that exhibits superior efficacy with reduced toxicity in preclinical experiments compared to existing anticancer drugs.  Phosplatin Therapeutics, a New York based Biotechnology Company, has licensed his anticancer agents and is preparing application for seeking clinical trail from FDA. His research has been supported by several grants from the National Science Foundation, National Institutes of Health, Ohio Board of Regents, and the U.S. Department of Education. 

Dr. Bose has served as a reviewer for funding agencies, many journals, an ad hoc member of a NIH Study Section, a NSF panel member, and a member of the editorial boards of three journals.